Subcutaneous Low Doses of Interleukin-2 and Recombinant Interferon Alpha with Carboplatin and Vinblastine in Patients with Advanced Melanoma1

Oncology ◽  
1997 ◽  
Vol 55 (1) ◽  
pp. 48-52 ◽  
Author(s):  
D. Bafaloukos ◽  
G. Fountzilas ◽  
D. Skarlos ◽  
N. Pavlidis ◽  
C. Bakoyiannis ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Interleukin 2 ◽  
Advanced Melanoma ◽  
Low Doses ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

scholarly journals Non-AIDS-Associated Kaposi's Sarcoma (Classical and Endemic African Types): Treatment with Low Doses of Recombinant Interferon-Alpha

1990 ◽  
Vol 95 (6) ◽  
pp. S176-S179 ◽  
Author(s):  
Michel Rybojad ◽  
Luca Borradori ◽  
Olivier Verola ◽  
Jeanne Zeller ◽  
Antoine Puissant ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Low Doses ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

1989 ◽  
Vol 7 (11) ◽  
pp. 1726-1732 ◽  
Author(s):  
K H Lee ◽  
M Talpaz ◽  
J M Rothberg ◽  
J L Murray ◽  
N Papadopoulos ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Patients ◽  
Interferon Alpha ◽  
Metastatic Cancer ◽  
Performance Status ◽  
Interleukin 2 ◽  
Repeated Treatment ◽  
Recombinant Interferon ◽  
Phase Ii Studies ◽  
Recombinant Interferon Alpha

Twenty-seven patients with metastatic cancer were treated with a daily continuous intravenous (IV) infusion of recombinant human interleukin-2 (rhIL-2) along with daily intramuscular recombinant interferon-alpha-2a (rIFN-alpha-2a) 4 days per week for 4 weeks with repeated treatment after 2 to 4 weeks of rest. The maximum-tolerated dose (MTD) was 3 million U/m2/d of rhIL-2 with 5 to 10 million U/m2/d of rIFN-alpha-2a. The dose-limiting toxicities are moderate hypotension requiring low doses of pressors and chronic fatigue associated with decreased performance status. Other common side effects included fever, chills, fluid retention, nausea/vomiting, erythrodermia, weight loss, elevated liver transminase levels, anemia, thrombocytopenia, and CNS toxic effects. There were seven objective responses among 25 evaluable patients. Four major responses (one complete response and three partial responses) were observed among 10 patients with melanoma treated with the MTD level. These data suggest that for cancer patients, concomitant rhIL-2 and rIFN-alpha-2a therapy is tolerable and has manageable side effects. Further phase II studies will be needed to define the antitumor activity of this combination.

Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer

1988 ◽  
Vol 85 (2) ◽  
pp. 147-151 ◽  
Author(s):  
Drew J. Winston ◽  
Lawrence J. Eron ◽  
Monto Ho ◽  
George Pazin ◽  
Harold Kessler ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Interferon Alpha ◽  
Recombinant Interferon ◽  
Patients With Cancer ◽  
Immunosuppressed Patients ◽  
Recombinant Interferon Alpha
Sign in / Sign up

Export Citation Format

Share Document